Bellerophon Therapeutics, Inc. (BLPH): Price and Financial Metrics

Bellerophon Therapeutics, Inc. (BLPH): $1.05

0.11 (+11.70%)

POWR Rating

Component Grades













Add BLPH to Watchlist
Sign Up

Industry: Biotech



in industry

BLPH Stock Price Chart Interactive Chart >

Price chart for BLPH

BLPH Price/Volume Stats

Current price $1.05 52-week high $5.95
Prev. close $0.94 52-week low $0.67
Day low $1.00 Volume 25,400
Day high $1.07 Avg. volume 55,133
50-day MA $1.66 Dividend yield N/A
200-day MA $2.79 Market Cap 10.02M

Bellerophon Therapeutics, Inc. (BLPH) Company Bio

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is founded in Warren, New Jersey.

BLPH Latest News Stream

Event/Time News Detail
Loading, please wait...

BLPH Latest Social Stream

Loading social stream, please wait...

View Full BLPH Social Stream

Latest BLPH News From Around the Web

Below are the latest news stories about Bellerophon Therapeutics Inc that investors may wish to consider to help them evaluate BLPH as an investment opportunity.

Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Naseem Amin, M.D., Chairman of Bellerophon’s Board of Directors, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022. The Company’s presentation will be available on-demand

Yahoo | January 10, 2022

Bellerophon Stock Has Massive Upside Potential, Says Analyst

Last Friday, Bellerophon (BLPH) announced positive top-line data from a recently concluded Phase 2 dose escalation study (PULSE-PHPF-002), looking at the acute hemodynamic benefit of Bellerophon’s INOpulse system as a therapy for pulmonary hypertension associated with sarcoidosis (PH-Sarc). The Phase 2 testing was set up as a proof of concept study to see if the system could show hemodynamic benefit in PH-Sarc.  The results were promising, as across the three doses used in the study, all 8 subjects displayed a reduction in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). The treatment appears safe too, with no adverse events noted.

Marty Shtrubel on TipRanks | December 22, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday!

William White on InvestorPlace | December 20, 2021

Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment was safe and well-tolerated, with no treatment-emergent adverse events observed during the acute hemodynamic dose escalation phase of the study WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments fo

Yahoo | December 17, 2021

Northern Trust Corp Cuts Position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH)

Northern Trust Corp lessened its position in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 51.6% in the 2nd quarter, reports. The institutional investor owned 36,555 shares of the biotechnology companys stock after selling 39,024 shares during the quarter. Northern Trust Corps holdings in Bellerophon Therapeutics were worth $177,000 at the end of the most []

Transcript Daily | December 6, 2021

Read More 'BLPH' Stories Here

BLPH Price Returns

1-mo -27.08%
3-mo -55.88%
6-mo -66.88%
1-year -74.64%
3-year -88.88%
5-year -94.89%
YTD -66.13%
2021 -53.52%
2020 27.16%
2019 -56.29%
2018 -68.99%
2017 396.15%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.956 seconds.